0
USD
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Methicillin-resistant Staphylococcus aureus (MRSA) -Epidemiology Forecast to 2028
Published Date: April 2019
|
Report Code: DELV-Epid-442
Home | Market Reports |Health |Health Conditions |Infectious Diseases
Methicillin resistant Staphylococcus aureus Epidemiology Forecast to 2028

Methicillin-resistant Staphylococcus aureus (MRSA) -Epidemiology Forecast to 2028

Code: DELV-Epid-442
Report
April 2019
50 Pages
Delveinsight
Region: Global,
Description
Table of Content
Tables & Figures

DelveInsight's "Methicillin-resistant Staphylococcus aureus (MRSA) - Epidemiology Forecast, 2028” report provides a comprehensive analysis of the Methicillin-resistant Staphylococcus aureus (MRSA) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Methicillin-resistant Staphylococcus aureus (MRSA) Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Methicillin-resistant Staphylococcus aureus (MRSA) in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Methicillin-resistant Staphylococcus aureus (MRSA) outlook. It also includes the explanation of changing trends of epidemiology outlining the Methicillin-resistant Staphylococcus aureus (MRSA) scenario.

Methicillin-resistant Staphylococcus aureus (MRSA) Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Methicillin-resistant Staphylococcus aureus (MRSA) thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Methicillin-resistant Staphylococcus aureus (MRSA) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Methicillin-resistant Staphylococcus aureus (MRSA) Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Methicillin-resistant Staphylococcus aureus (MRSA)

Key assessments
• Patient Segmentation in Methicillin-resistant Staphylococcus aureus (MRSA)
• Methicillin-resistant Staphylococcus aureus (MRSA) Risk & Burden
• Factors driving growth in a specific Methicillin-resistant Staphylococcus aureus (MRSA) patient population

1. Report Introduction
2. Methicillin-resistant Staphylococcus aureus (MRSA) Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Methicillin-resistant Staphylococcus aureus (MRSA) in 2016
2.2. Patient Share Distribution of Methicillin-resistant Staphylococcus aureus (MRSA) in 2028
3. Disease Background and Overview: Methicillin-resistant Staphylococcus aureus (MRSA)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Methicillin-resistant Staphylococcus aureus (MRSA) in 7MM
4.3. Total Prevalent/ Incident Patient Population of Methicillin-resistant Staphylococcus aureus (MRSA) in 7MM – By Countries
5. Epidemiology of Methicillin-resistant Staphylococcus aureus (MRSA) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)
5.1.3. Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) *
5.1.4. Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)*
5.1.5. Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)
5.4.3. Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA)*
5.4.4. Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)*
5.4.5. Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)
5.5.3. Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA)*
5.5.4. Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)*
5.5.5. Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)
5.6.3. Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA)*
5.6.4. Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)*
5.6.5. Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)
5.7.3. Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA)*
5.7.4. Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)*
5.7.5. Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)
5.8.3. Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA)*
5.8.4. Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)*
5.8.5. Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)
5.9.3. Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA)*
5.9.4. Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)*
5.9.5. Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)
6. Unmet Needs of the Methicillin-resistant Staphylococcus aureus (MRSA)
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

List of Tables :

Table 1: Total Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in 7MM
Table 2: Total Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in United States (2016-2028)*
Table 6: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in France (2016-2028) *
Table 13: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in France (2016-2028) *
Table 14: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in UK (2016-2028) *
Table 26: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Japan (2016-2028)

List of Figures :

Figure 1: Total Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in France (2016-2028) *
Figure 14: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Japan (2016-2028)

DelveInsight's "Methicillin-resistant Staphylococcus aureus (MRSA) - Epidemiology Forecast, 2028” report provides a comprehensive analysis of the Methicillin-resistant Staphylococcus aureus (MRSA) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Methicillin-resistant Staphylococcus aureus (MRSA) Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Methicillin-resistant Staphylococcus aureus (MRSA) in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Methicillin-resistant Staphylococcus aureus (MRSA) outlook. It also includes the explanation of changing trends of epidemiology outlining the Methicillin-resistant Staphylococcus aureus (MRSA) scenario.

Methicillin-resistant Staphylococcus aureus (MRSA) Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Methicillin-resistant Staphylococcus aureus (MRSA) thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Methicillin-resistant Staphylococcus aureus (MRSA) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Methicillin-resistant Staphylococcus aureus (MRSA) Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Methicillin-resistant Staphylococcus aureus (MRSA)

Key assessments
• Patient Segmentation in Methicillin-resistant Staphylococcus aureus (MRSA)
• Methicillin-resistant Staphylococcus aureus (MRSA) Risk & Burden
• Factors driving growth in a specific Methicillin-resistant Staphylococcus aureus (MRSA) patient population

Read More

1. Report Introduction
2. Methicillin-resistant Staphylococcus aureus (MRSA) Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Methicillin-resistant Staphylococcus aureus (MRSA) in 2016
2.2. Patient Share Distribution of Methicillin-resistant Staphylococcus aureus (MRSA) in 2028
3. Disease Background and Overview: Methicillin-resistant Staphylococcus aureus (MRSA)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Methicillin-resistant Staphylococcus aureus (MRSA) in 7MM
4.3. Total Prevalent/ Incident Patient Population of Methicillin-resistant Staphylococcus aureus (MRSA) in 7MM – By Countries
5. Epidemiology of Methicillin-resistant Staphylococcus aureus (MRSA) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)
5.1.3. Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) *
5.1.4. Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)*
5.1.5. Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)
5.4.3. Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA)*
5.4.4. Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)*
5.4.5. Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)
5.5.3. Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA)*
5.5.4. Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)*
5.5.5. Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)
5.6.3. Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA)*
5.6.4. Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)*
5.6.5. Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)
5.7.3. Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA)*
5.7.4. Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)*
5.7.5. Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)
5.8.3. Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA)*
5.8.4. Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)*
5.8.5. Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)
5.9.3. Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA)*
5.9.4. Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)*
5.9.5. Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA)
6. Unmet Needs of the Methicillin-resistant Staphylococcus aureus (MRSA)
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

Read More

List of Tables :

Table 1: Total Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in 7MM
Table 2: Total Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in United States (2016-2028)*
Table 6: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in France (2016-2028) *
Table 13: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in France (2016-2028) *
Table 14: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in UK (2016-2028) *
Table 26: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Japan (2016-2028)

List of Figures :

Figure 1: Total Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in France (2016-2028) *
Figure 14: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Methicillin-resistant Staphylococcus aureus (MRSA) in Japan (2016-2028)

Read More
SELECT A FORMAT
Added to Cart

Single User

Electronic (PDF)
$3250
This license allows only one user to access the PDF.

Site License

Electronic (PDF)
$6500
This license allows all the users of an enterprise residing in one location to access the PDF

Enterprise License

Electronic (PDF)
$9750
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Accenture

RELATED REPORTS

Global Pets Pain Relief and Prevention Market Research Report 2021
Global Pets Pain Relief and Prevention Market Research Report 2021

120 Pages
Type: Report
Code: QYRE-Auto-28J2423
Tue Jun 15 00:00:00 UTC 2021

Add to Cart

Global Animal Pain Relief and Prevention Market Research Report 2021
Global Animal Pain Relief and Prevention Market Research Report 2021

120 Pages
Type: Report
Code: QYRE-Auto-11F2742
Tue Jun 15 00:00:00 UTC 2021

Add to Cart

Global Trivalent Flu Vaccine Sales Market Report 2021
Global Trivalent Flu Vaccine Sales Market Report 2021

120 Pages
Type: Report
Code: QYRE-Auto-19B5144
Mon Jun 14 00:00:00 UTC 2021

Add to Cart

Global Quadrivalent Flu Vaccine Sales Market Report 2021
Global Quadrivalent Flu Vaccine Sales Market Report 2021

120 Pages
Type: Report
Code: QYRE-Auto-21C5159
Mon Jun 14 00:00:00 UTC 2021

Add to Cart

0 Items
X
No items in the cart.
$0.0